Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) | RFA NS 18 043

Opportunity Information: Apply for RFA NS 18 043

The NIH funding opportunity titled "Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)" (RFA-NS-18-043) supports basic science research aimed at finding and firmly validating new biological targets that could eventually lead to safer, more effective pain treatments. The central idea is to expand the pipeline of promising pain targets by encouraging investigators to look across multiple body systems, including the peripheral nervous system, central nervous system, immune system, and other relevant tissues, and to produce strong evidence that a proposed target genuinely influences pain in a reliable and reproducible way. A major emphasis is placed on identifying targets that could enable pain relief with minimal side effects and, importantly, little to no abuse or addiction potential, reflecting a broader public health need for non-addictive analgesic strategies.

A key feature of this FOA is the requirement for rigorous target validation, not just target discovery. Applicants are expected to go beyond an initial observation and include studies that demonstrate robustness, such as confirming that the target is causally involved in pain mechanisms, showing consistent effects across appropriate experimental systems, and using well-justified approaches to reduce the chance of false positives. The practical reason for this requirement is risk reduction: by funding careful validation up front, the FOA aims to make subsequent translational efforts more likely to succeed when groups later attempt to develop small molecules, biologics, natural substances, or other interventions that engage the validated target. While the long-term vision is clearly to enable therapeutic development, this particular announcement is not meant to fund late-stage translational programs or clinical testing, and it explicitly indicates that clinical trials are not allowed under this mechanism.

In scope, the FOA is broad with respect to pain conditions and is not limited to any single disease area. Proposals may focus on acute pain or chronic pain and can target specific disorders such as migraine and other headache conditions, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, and post-stroke pain, among others. It also welcomes applications that address chronic overlapping pain conditions or pain associated with particular pathological states. Another explicitly encouraged direction is the identification of novel targets that are especially relevant to specific populations, including women, children, older adults, and other underrepresented groups, which aligns with the need to understand pain biology across diverse patient communities and improve the relevance of future therapies.

The FOA uses the NIH R01 grant mechanism and falls under the discretionary grant category. It is administered by the National Institutes of Health, with multiple listed CFDA numbers indicating relevance across several NIH programs and institutes that support neuroscience, drug abuse, and broader biomedical research portfolios. The funding opportunity was created on September 19, 2018, and the original closing date listed is November 12, 2019. No award ceiling or expected number of awards is specified in the provided source data, which typically means applicants should consult the full FOA for budget expectations and any institute-specific guidance.

Eligibility is intentionally expansive. In addition to the standard range of domestic applicants such as public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (including entities other than small businesses), small businesses, and various levels of government (state, county, city/township, special districts), the FOA also highlights eligibility for a wide set of mission-relevant institutions and organizations. These include Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, tribal governments and tribal organizations (including those other than federally recognized), faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and even non-U.S. (foreign) entities. Taken together, the structure and eligibility reflect an attempt to draw innovative target discovery and validation ideas from a broad research ecosystem, with the shared goal of enabling future pain treatments that are both effective and safer from a side-effect and addiction-risk standpoint.

• The National Institutes of Health in the education, food and nutrition, health, income security and social services sector is offering a public funding opportunity titled "Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.273, 93.279, 93.361, 93.393, 93.846, 93.847, 93.853, 93.865, 93.866, 93.867, 93.879.
• This funding opportunity was created on 2018-09-19.
• Applicants must submit their applications by 2019-11-12. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA NS 18 043

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: